# Icotinib Hydrochloride in Treating Patients With Advanced Cancers

> **NCT02033148** · PHASE1 · WITHDRAWN · sponsor: **Roswell Park Cancer Institute**

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** icotinib hydrochloride
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT02033148
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-08
- **Primary completion:** 2016-06
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** changes in study design by sponsor not acceptable for participating
- **Last updated:** 2014-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02033148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02033148, "Icotinib Hydrochloride in Treating Patients With Advanced Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02033148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*